

***鄭恩加教授**

所有發表期刊論文、研討會及著作

(*Corresponding author 通訊作者之論文)

1. Lu YC, Chang JT, Huang YC, Huang CC, Chen WH, Lee LY, Huang BS, Chen YJ, Li HS, **Cheng AJ***. (2015.01) Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. Clin Biochem (in press)
2. Lu YC, Chang JT, Liao CT, Kang CJ, Huang SF, Chen IH, Huang CC, Huang YC, Chen WH, Tsai CY, Wang HM, Yen TC, You GR, Chiang CH, **Cheng AJ***. (2014.09) OncomiR-196 promotes an invasive phenotype in oral cancer through the NEM4-JNK-TIMP1-MMP signaling pathway. Mol Cancer 2014, 13:218. doi:10.1186/1476-4598-13-218. PMID: 25233933
3. MicroRNA miR-218, mir-125b, and let-7g predict prognosis in patients with oral cavity squamous cell carcinoma. Peng SC, Liao CT, Peng CH, **Cheng AJ**, Chen SJ, Huang CG, Hsieh WP, Yen TC. (2014.07) PLoS One 2014, 9: e102403. doi: 10.1371/journal.pone.0102403. PMID: 25050624
4. Lu YC, **Cheng AJ***. (2014.05). Pathological function and clinical significance of microRNA-10b in cancer. Cancer Sci Res Open Assess 1(2): 1-5
5. Yen YC, Shiah SG, Chu HC, Hsu YM, Hsiao JR, Chang JY, Hung WC, Liao CT, **Cheng AJ**, Lu YC, Chen YW. (2014.01) Reciprocal regulation of microRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells. Mol Cancer 2014, 13:6. doi:10.1186/1476-4598-13-6, PMID: 24410957.
6. Huang WC, Chan SH, Jang TH, Chang JW, Ko YC, Yen TC, Chiang SL, Chiang WF, Shieh TY, Liao CT, Juang JL, Wang HC, **Cheng AJ**, Lu YC, Wang LH. (2014.02) miRNA-491-5p and GIT1 Serve as Modulators and Biomarkers for Oral Squamous Cell Carcinoma Invasion and Metastasis. Cancer Res 2014, 74:751-64. doi:10.1158/0008-5472.CAN-13-1297. PMID: 24335959.
7. Chiu CC, Lee LY, Li YC, Chen YJ, Lu YC, Li YL, Wang HM, Chang JTC, **Cheng AJ***. (2013.11) Grp78 as a therapeutic target for refractory head-neck cancer with CD24-CD44+ stemness phenotype. Cancer Gene Ther 2013, 20: 606-615. doi: 10.1038/cgt.2013.64. PMID: 24201869.
8. Lee CH, Wong TS, Chan JY, Lu SC, Lin P, **Cheng AJ**, Chen YJ, Chang JS, Hsiao SH, Leu YW, Li CI, Hsiao JR, Chang JY. (2013.07) Epigenetic regulation of the X-linked tumor suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. J Pathol 2013, 230: 298-309.
9. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, **Cheng AJ**, et al. (2013.06) Identification of targetable EGFR

- gene fusions in diverse cancers. *Cancer Discov* 2013, 3:636-647. doi: 10.1158/2159-8290.CD-13-0050. PMID: 23558953.
10. Jian SL, Hsieh HY, Liao CT, Yen TC, Nien SW, **Cheng AJ**, Juang JL. (2013.06) Ga12 drives invasion of oral squamous cell carcinoma through up-regulation of proinflammatory cytokines. *PLoS One* 2013, 8: e66133. doi: 10.1371/journal.pone.0066133. PMID: 23762476.
 11. Chen YJ, Lee LY, Chao YK, Chang JT, Lu YC, Li HF, Chiu CC, Li YL, Chiou JF, **Cheng AJ***. (2013.05) DSG3 facilitates cancer cell growth and invasion through the DSG3- plakoglobin - TCF/LEF - myc / cyclinD1 / MMP signaling pathway. *PLoS One* 2013, 8:e60488. doi: 10.1371/journal.pone.0064088. PMID: 23737966.
 12. Le QT, Zhang Q, Cao H, **Cheng AJ**, Pinsky BA, Hong RL, Chang JT, Wang CW, Tsao KC, Lo YD, Lee NY, Ang KK, Chan AT, Chan KA. (2013.04) An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus (EBV) DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. *Clin Cancer Res* 2013, 19: 2208-2015. doi: 10.1158/1078-0432.CCR-12-3702. PMID: 23459720.
 13. Huang SF, Li HF, Liao CT, Wang HM, Chen IH, Chang JTC, Chen YJ, **Cheng AJ***. (2012. 11) Association of HPV infection with second primary tumors in early staged oral cavity cancer. *Oral Disease* 2012, 18: 809-815. doi: 10.1111/j.1601-0825.2012.01950.x. PMID: 22747969.
 14. Tsai JP, Lee MH, Hsu SC, Chen MY, Liu SJ, Chang JT, Liao CT, **Cheng AJ**, Chong P, Chu CL, Shen CR, Chen HW. (2012.08) CD4+ T cells disarm or delete cytotoxic T lymphocytes under IL-17 polarizing conditions. *J Immunol* 2012, 189: 1671-1679. doi: 10.4049/jimmunol.1103447. PMID: 22798680.
 15. Lu YC, Chen YJ, Wang HM, Tsai CY, Chen WH, Huang YC, Fan KH, Tsai CN, Huang SF, Kang CJ, Chang JT, **Cheng AJ***. (2012.04) Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. *Cancer Prev Res* 2012, 5:665-674. doi: 10.1158/1940-6207.CAPR-11-0358. PMID: 22318752.
 16. Chao YK, Chuang WY, Yeh CJ, Wu YC, Liu YH, Hsieh MJ, **Cheng AJ**, Hsueh C, Liu HP (2012, 02). Prognostic significance of high podoplanin expression after chemoradiotherapy in esophageal squamous cell carcinoma patients. *J Surg Oncol* 2012, 105:183-188. doi: 10.1002/jso.22068. PMID: 22213642.
 17. Lin CY, Lin TY, Wang HM, Huang SF, Fan KH, Liao CT, Chen IH, Lee LY, Li YL, Chen YJ, **Cheng AJ***, Chang JT. (2011.11) GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy. *Radiat Oncol* 2011, 6: 136-143. doi: 10.1186/1748-717X-6-136. PMID: 21992474.

18. Peng CH, Liao CT, Peng SC, Chen YJ, **Cheng AJ**, Juang JL, Tsai CY, Chen TC, Chuang YJ, Tang CY, Hsieh WP, Yen TC. (2011.06) A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. *PLoS One*. 2011, 6:e23452. doi: 10.1371/journal.pone.0023452. PMID: 21853135.
19. Chiu CC, Lin CY, Lee LY, Chen YJ, Lu YC, Wang HM, Liao CT, Chang JT, Cheng **AJ***. (2011, 07) Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer. *Clin Cancer Res* 2011, 17: 4629-4641. doi: 10.1158/1078-0432.CCR-10-2107. PMID: 21642380.
20. Chen YJ, Liao CT, Chen PJ, Lee LY, Li YC, Chen IH, Wang HM, Chang JTC, Chen LJ, Yen TC, Tang CY, **Cheng AJ***. (2011, 3) Down-regulation of Ches1 and other novel genes in oral cancer cells chronically exposed to areca nut extract. *Head Neck* 2011, 33: 257-266. doi: 10.1002/hed.21442.. PMID: 20848451.
21. Chang JTC, Kuo TF, Chen YJ, Chiu CC, Lu YC, Li HS, Wang HM, Shen CR, **Cheng AJ***. (2010, 12) Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. *Cancer Gene Ther* 2010, 17: 827-836. doi: 10.1038/cgt.2010.38. PMID: 20885450.
22. Lin TY, Chang JTC, Wang HM, Chan SH, Chiu CC, Lin CY, Fan KH, Liao CT, Chen IH, Liu TZ, Li HF, **Cheng AJ***. (2010.09) Proteomics of the radioresistant phenotype in head-and-neck cancer: GP96 as a novel prediction marker and sensitizing target for radiotherapy. *Int J Radiat Oncol Biol Phys* 2010, 78: 246-256. doi: 10.1016/j.ijrobp.2010.03.002. PMID: 20615631.
23. Lin CY, Chen WH, Liao CT, Chen IH, Chiu CC, Wang HM, Yen TC, Lee LY, Chang JT, **Cheng AJ***. (2010, 8) Positive association of Grp78 during oral cancer progression and the prognostic value in oral precancer lesions. *Head Neck* 2010, 32: 1028-1039. doi: 10.1002/hed.21287. PMID: 19953611.
24. Liao CT, Wang HM, Chang JT, Lin CY, Ng SH, Huang SF, Chen IH, Hsueh C, Lee LY, Lin CH, **Cheng AJ**, Yen TC. (2010.06) Influence of pathological nodal status and maximal standardized uptake value of the primary tumor and regional lymph nodes on treatment plans in patients with advanced oral cavity squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*. 2010; 77: 421-429. doi: 10.1016/j.ijrobp.2009.05.002. PMID: 20457351.
25. Wu YH, Wang HM, Chen HW, Lin CY, Chen YE, Fan KH, Huang SF, Chen IH, Liao CT, **Cheng AJ**, Chang JT. (2010, 3) Hypothyroidism after radiotherapy for nasopharyngeal cancer patients. *Int J Radiat Oncol Biol Phys* 2010, 76: 1133-1139. doi: 10.1016/j.ijrobp.2009.03.011. PMID: 19596170.
26. Chao YK, Yeh CJ, Chuang WY, Fan KH, Hsieh MJ, Chu Y, **Cheng AJ**, Liu HP. (2009, 12) Prognostic significance of immunohistochemically detected lymph node

- micrometastases in pT0N0 esophageal squamous cell carcinoma. *J Surg Oncol* 2009, 100: 559-562.
27. Kang CJ, Chen YJ, Liao CT, Wang HM, Chang JT, Lin CY, Lee LY, Wang TH, Yen TC, Shen CR, Chen IH, Chiu CC, **Cheng AJ***. (2009, 11) Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer. *Cancer Lett* 2009, 284: 131-140.
 28. Liao CT, Chang JT, Wang HM, Ng SH, Huang SF, Chen IH, Hsueh C, Lee LY, Lin CH, **Cheng AJ**, Yen TC. (2009, 11) Preoperative [(18)F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse. *Eur J Nucl Med Mol Imaging* 2009, 36: 1783- 1793.
 29. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, **Cheng AJ**, Yen TC. (2009, 6) Preoperative [18F]fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. *Int J Radiat Oncol Biol Phys* 2009, 74:1054-1061.
 30. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, **Cheng AJ**, See LC, Yen TC. (2009, 3) Pretreatment primary tumor SUVmas measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. *Int J Radiat Oncol Biol Phys* 2009, 73: 764-771.
 31. Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, **Cheng AJ**, Yen TC. (2009, 1) Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery. *Ann Surg Oncol* 2009, 16: 159-170.
 32. Chiu CC, Lin CY, Lee LY, Chen YJ, Kuo TF, Chang JTC, Liao CT, Wang HM, Yen TC, Shen CR, Liao SK, **Cheng AJ***. (2008, 9) Glucose-regulated protein 78 regulates multiple malignant phenotypes in head-neck cancer and may serve as a molecular target of therapeutic intervention. *Mol Cancer Ther* 2008, 7: 2788-2797.
 33. Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, **Cheng AJ**, Yen TC. (2008, 8) When does skin excision allow the achievement of an adequate local control rate in patients with squamous cell carcinoma involving the buccal mucosa? *Ann Surg Oncol* 2008, 15: 2187-2194.
 34. Chen YJ, Chang JTC, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, **Cheng AJ***. (2008, 8) Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. *Cancer Sci* 2008, 99: 1507-1514.

35. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, **Cheng AJ**, See LC, Yen TC. (2008, 6) Does adjuvant radiation therapy improve outcome in pT1-3N0 oral cavity cancer with tumor-free margins and perineural invasion? *Int J Radiat Oncol Biol Phys* 2008, 71: 371-376.
36. Lin CY, Lee LY, Huang SF, Kang CJ, Fan KH, Wang HM, Chen EY, Chen IH, Laio CT, **Cheng AJ**, Chang JT. (2008, 4) Treatment outcome of combined modalities for buccal cancer: unilateral or bilateral neck radiation? *Int J Radiat Oncol Biol Phys* 2008, 70: 1373-1381.
37. Huang SF, Kang CJ, Lin CY, Fan KH, Yen TC, Wang HM, Chen IH, Liao CT, **Cheng AJ**, Chang JT. (2008, 3) Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. *Cancer* 2008, 112: 1066-1075.
38. Liao CT, Chang JT, Wang HM, NgSH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, **Cheng AJ**, Yen TC. (2008, 3) Analysis of risk factors of predictive local tumor control in oral cavity cancer. *Ann Surg Oncol* 2008, 15: 912-922.
39. Liao CT, Chang JT, Wang HM, NgSH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, **Cheng AJ**, Yen TC. (2008, 1) Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: How and when? *Cancer* 2008, 112: 94-103.
40. Lee LA, **Cheng AJ**, Fang TJ, Huang CG, Liao CT, Chang JT, Li HY. (2008, 1) High incidence of malignant transformation of laryngeal papilloma in Taiwan. *Laryngoscope* 2008, 118: 50-55.
41. Chen YJ, **Cheng AJ***. (2007, 12) Desmosome proteins play roles in carcinogenesis. *J Stomatol Invest* 2007, 1: 69-71.
42. Chang JT, Chen CJ, Lin YC, Chen YC, Lin CY, **Cheng AJ**. (2007, 9) Health-related quality of life and patient satisfaction after treatment for breast cancer in northern Taiwan. *Int J Radiat Oncol Biol Phys* 2007, 69: 49-53.
43. Chang JTC, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT, Wang TH, Lee LY, **Cheng AJ***. (2007, 8) Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. *Mol Cancer Ther* 2007, 6: 2271-2279.
44. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, **Cheng AJ**, Yen TC. (2007, 8) Survival in squamous cell carcinoma of the oral cavity: differences between pT4 N0 and other stage IVA categories. *Cancer* 2007, 110: 564-571.
45. Chen YJ, Chang JT, Lee Ly, Wang HM, Liao CT, Chiu CC, Chen PJ, **Cheng AJ***. (2007, 1) DSG3 is over- expressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. *Oncogene* 2007, 26: 467-476.
46. Fan KH, Lin CY, Kang CJ, Huang SF, Wang HM, Chen EY, Chen IH, Liao CT, **Cheng AJ**, Chang JT. (2007, 2) Combined-modality treatment for advanced oral tongue

- squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 2007, 67: 453-461.
47. Liao CT, Kang CJ, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, **Cheng AJ**, Chen IH, Huang SF, Yen TC. (2007, 2) Survival of second and multiple primary tumors in patients with oral cavity squamous cell carcinoma in the betel quid chewing area. *Oral Oncol* 2007, 43: 811-819.
 48. Chang JTC, Chen LC, Wei SY, Chen YJ, Wang HM, Liao CT, Chen IH, **Cheng AJ***. (2006, 12) Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry - plasma peptidomes from nasopharyngeal cancer patients for example. *Clin Biochem* 2006, 39: 1144-1151.
 49. Yen TC, Lin CY, Wang HM, Huang SF, Liao CT, Kang CJ, Ng SH, Chan SC, Fan KH, Chen IH, Lin WJ, **Cheng AJ**, Chang JT. (2006, 8) (18)F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2006, 65: 1307-1341.
 50. Chang JT, Lu YC, Chen YJ, Tseng CP, Chen YL, Fang CW, **Cheng AJ***. (2006, 3) hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. *Br J Cancer* 2006, 94:870-874.
 51. **Cheng AJ***, Chen LC, Chien KY, Chen JY, Chang JTC, Wang HM, Liao CT, Chen IH. (2005, 12) Oral cancer plasma tumor marker identified with bead-based affinity fractionated proteomic technology. *Clin Chem* 2005, 51:2236-2244.
 52. Chang JT, Huei-Ting Yang, Wang TCV, **Cheng AJ***. (2005, 11) Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells. *Mol Carcinog* 2005, 44:183-192.
 53. Chang JT, Lin CY, Chen TM, Kang CJ, Ng SH, Chen IH, Wang HM, **Cheng AJ**, Liao CT. (2005, 10) Nasopharyngeal carcinoma with cranial nerve palsy: the importance of MRI for radiotherapy. *Int J Radiat Oncol Biol Phys* 2005, 63:1354-1360.
 54. Chang JT, Chang KW, Chen WH, Wang HM, Hsu YM, Yung BYM, Chen IH, Liao CY, Chen TM, Hsieh LL, **Cheng AJ***. (2005, 5) Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): over-expression of NPM, CDK1, NDRG1 and under-expression of CHES1. *Int J Cancer* 2005, 114: 942-949.
 55. Hsieh LL, Huang TH, Chen IH, Liao CT, Wang HM, Lai CH, Liou SH, Chang JT, **Cheng AJ**. (2005, 1) p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. *Br J Cancer* 2005, 92: 30-35.
 56. Tsui KH, **Cheng AJ**, Chang PE, Pan TL, Yung BY. (2004, 10) Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with

- bladder carcinoma. *Urology* 2004, 64: 839-844.
57. Chang JT, Wong FW, Liao CT, Chen IH, Wang HM, **Cheng AJ***. (2004, 7) Enzyme immunoassay for autoantibody to serum survivin and its finding in head and neck cancers. *Clin Chem* 2004, 50: 1261-1264.
 58. Liao CT, Chang JT, Wang HM, Chen IH, Lin CY, Chen TM, Hsieh LL, **Cheng AJ***. (2004, 6) Telomerase as an independent prognostic factor in head and neck squamous cell carcinoma. *Head Neck* 2004, 26: 504-512.
 59. Liao CT, Chen IH, Chang JT, Wang HM, Hsieh LL, **Cheng AJ***. (2003, 9) Lack correlation of betel nut, tobacco smoking or alcohol consumption with telomerase activity and the severity of oral cancer. *Chang Gung Med J* 2003, 26: 637-645.
 60. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, **Cheng AJ***. (2003, 8) Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area. *Brit J Cancer* 2003, 89: 681-686.
 61. Hsieh LL, Chien HT, Chen IH, Liao CT, Wang HM, Jung SM, Wang PF, Chang JT, Chen MC, **Cheng AJ**. (2003, 5) The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. *Cancer Epidemiol Biomarkers Prev* 2003, 12: 439-443.
 62. Lin YC, Chou YHW, Liao IC, and **Cheng AJ***. (2003, 2) The expression of mammaglobin mRNA in metastatic breast cancer patients as an adjunct to serum tumor markers. *Cancer Letters* 2003, 191: 93-99.
 63. Lin YC, Chen SC, Hsueh S, Lo YF, Chow-Wu YH, Liaw IC, and **Cheng AJ**. (2003, 1) Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. *Cancer Sci* 2003, 94: 99-102.
 64. Chang JT, Chen IH, Liao CT, Wang HM, Hsu YM, Hung KF, Lin CJ, Hsieh LL and **Cheng AJ***. (2002, 11) A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. *Clin Biochem* 2002, 35: 591-596.
 65. Tseng CP, **Cheng AJ**, Chang JTC, Tsehng CH, Wang HM, Liao CT, Chen IH, Tseng KC (2002, 11). Quantitative analysis of multidrug-resistance *mdr1* gene expression in head and neck cancer by real-time RT-PCR. *Jpn J Cancer Res* 2002, 93: 1230-1236.
 66. Chang JT, Chen YL, Yang HT, Chen CY, and **Cheng AJ***. (2002, 7) Differential regulation of telomerase activity by six telomerase subunits. *Eur J Biochem* 2002, 269: 3442-3450.
 67. Chang KW, Kao SY, Tzeng RJ, Liu CJ, **Cheng AJ**, Yang SC, Wong YK, and Lin SC. (2002, 3) Multiple molecular alterations of FHIT in betel-associated oral

- carcinoma. *J Pathol* 2002, 196: 300-306.
68. Hsieh LL, Wang PF, Chen IH, Liao CT, Wang HM, Chen MC, Chang TC, and **Cheng AJ**. (2001, 9) Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. *Carcinogenesis* 2001, 22: 1497-1503.
 69. **Cheng AJ**, Chiu DT-Y, See L-C, Liao C-T, JT Chang. (2001, 5) Poor prognosis in nasopharyngeal cancer patients with low glucose-6-phosphate-dehydrogenase activity. *Jpn J Cancer Res* 2001, 92: 576-581.
 70. Chang JTC, Chen CC, Lee SH, Ho JU, **Cheng AJ**, Hong JH. (2000, 12) Comparison of treatment plans for nasopharyngeal carcinoma: bil-lateral opposing, 3D conformal and intensity modulated radiotherapy. *Therapeutic Radiol Oncol* 2000, 7: 267-274.
 71. Chang JTC, Liao C-T, Jung S-M, Wang TV, See LC and **Cheng AJ***. (2000, 6) Telomerase activity is frequently found in metaplastic and malignant human nasopharyngeal tissues. *Brit J Cancer* 2000, 82: 1946-1951.
 72. Yeh T-A, **Cheng AJ**, Chen T-C, Jan Y-Y, Hung T-L, Jeng L-B, Chen M-F, Wang T-CV. (1999, 12) Telomerase activity is an useful marker to distinguish malignant pancreatic cystic tumor from benign neocysts and pseudocysts. *J Surg Res* 1999, 87: 171-177.
 73. **Cheng AJ**, Tang R, Wang JY, Chang JT, and Wang TV. (1999, 3) Polymerase chain reaction-based enzyme immunoassay for quantitation of telomerase activity: application to colorectal cancers. *Jpn J Cancer Res* 1999, 90: 280-285.
 74. Tang R, **Cheng AJ**, Wang J-Y, and Wang TV. (1998, 9) Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. *Cancer Res* 1998, 58: 4052-4054.
 75. **Cheng AJ**, Lin LD, Chang JT and Wang TV. (1998, 6) Telomerase activity in benign and malignant human thyroid disorders. *Brit J Cancer* 1998, 77: 2177-2180.
 76. **Cheng AJ**, Wang JC and Van Dyke MW. (1998, 6) Self-association of G-rich oligodeoxy- ribonucleotides under conditions promoting purine-motif triplex formation. *Antisense Nucleic Acid Drug Dev* 1998, 8:215-225.
 77. Liu Y-H, **Cheng A-J**, Wang TV. (1998, 4) An involvement of recF, recO and recR genes in UV radiation mutagenesis of *Escherichia coli*. *J Bacteriol* 1998, 180: 1766-1770.
 78. **Cheng AJ**, Tang R, Wang JY, See LC and Wang TV. (1998, 2) Possible role of telomerase activation in the cancer predisposition of patients with hereditary nonpolyposis colorectal cancers. *J Natl Cancer Inst* 1998, 90: 316-321.
 79. Ku W-C, **Cheng AJ**, and Wang TV. (1997, 12) Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. *Biochem Biophys*

Res Commun 1997, 241: 730-736.

80. **Cheng AJ**, and Van Dyke MW. (1997, 9) Oligodeoxyribonucleotide length and sequence effects on intramolecular and intermolecular G-quartet formation. *Gene* 1997, 197: 253-260.
81. **Cheng AJ**, Liao S-K, Chow S-K, Chen J-K and Wang TV. (1997, 8) Differential inhibition of telomerase activity during induction of differentiation in hematopoietic, melanoma and glioma cells in culture. *Biochem Biophys Res Commun* 1997, 237: 438-444.
82. **Cheng AJ**, Chang JC, Juan G, and Liu T-Z. (1997) Diagnostic efficacy of a monoclonal antibody-based sandwich enzyme linked immunosorbent assay procedure for quantitation of prostatic acid phosphatase. *J Biomed Lab Sci* 1997, 9: 22-27.
83. **Cheng AJ**, Lam K-W, Liu M, and Liu T-Z. (1995) Development of a monoclonal antibody-based enzyme linked immunosorbent assay for the quantitation of prostatic acid phosphatase. *J Biomed Lab Sci* 1995, 7: 91-96.
84. **Cheng AJ**, and Van Dyke MW. (1994, 11) Oligodeoxyribonucleotide length and sequence effects on intermolecular purine-purine-pyrimidine triple-helix formation. *Nucleic Acids Res* 1994, 22: 4742-4747.
85. **Cheng AJ**, and Van Dyke MW. (1993, 12) Monovalent cation effects on intermolecular purine-purine-pyrimidine triple-helix formation. *Nucleic Acids Res* 1993, 21: 5630-5635.

B. Abstract Reports (International meeting, First author only)

1. **Cheng AJ**, et al (2014.04) Areca nut contributes to malignant phenotype through promoting the conversion of cancer stem cell. The 33rd European Society for Radiotherapy and Oncology (ESTRO) meeting. Vienna, Austria.
2. **Cheng AJ**, et al (2013, 4) Oncogenic function of miR-196s promote cell invasion through suppression of NME4 to regulate JNK-TIMP1-MMP signaling pathway in head and neck cancer. Proc Am Assoc Cancer Res Annual Meeting. The 104th AACR, Washington DC, USA.
3. **Cheng AJ**, et al (2012, 4) DSG3 facilitates cancer cell growth and invasion through DSG3- plakoglobin- FCF signaling pathway. Proc Am Assoc Cancer Res Annual Meeting. The 103rd AACR, Chicago, IL, USA.
4. **Cheng AJ**, et al (2011, 9) microRNA signature and functional characterization of miR-10b in oral cancer. The European Multidisciplinary Cancer Congress. Stockholm, Sweden.
5. **Cheng AJ**, et al (2011, 4) Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head-neck cancer. Proc Am Assoc Cancer Res

Annual Meeting. The 102nd AACR, Orland, FL, USA

6. **Cheng AJ**, et al (2010, 4) miRNA profiling in head and neck cancer. Proc Am Assoc Cancer Res Annual Meeting . The 101st AACR, Orland FL, USA.
7. **Cheng AJ**, et al (2009, 9) Comparative proteomics of the radioresistant phenotype in head and neck cancer: Gp96 as a novel prediction marker and radio-sensitizing target for radiotherapy. European Journal of Cancer, Supplements Vol 7 (2), 2009. The Joint ECCO15 – 34th ESMO Multidisciplinary Congress, Berlin, Germany.
8. **Cheng AJ**, et al (2009, 4) Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer. Proc Am Assoc Cancer Res Annual Meeting. The 100st AACR, Denver, CO, USA.
9. **Cheng AJ**, et al (2008, 7) The Oncogenic effects of Grp78 in head neck cancer. The 7th International Head Neck Meeting. (San Francisco, CA, USA)
10. **Cheng AJ**, et al (2008, 4) The SNPs in BTCA1/BRCA2 and their genetic susceptibility of oral cancer in Taiwan. Proc Am Assoc Cancer Res 49. The 99th AACR, San Diego, CA, USA
11. **Cheng AJ**, et al (2007, 4) Identification of GP96 and GDF15 as radioresistant genes in nasopharyngeal cancer. Proc Am Assoc Cancer Res 48: 741. (The 98th AACR, Las Angeles, CA, USA)
12. **Cheng AJ**, et al (2007, 2) Grp78 is over-expressed in head neck cancer and is a molecular target for inhibition of carcinogenesis in head neck cancer. Radiother Oncol 82 (sup 1): s24. (The international meeting on innovative approaches in head neck oncology, Barcelona, Spain)
13. **Cheng AJ**, et al (2006, 10) Characterization of GDF15 and Gp96 as radioresistant genes in head neck cancer. Radiother Oncol 81 (sup 1): s32. (The 25th ESTRO, Leipzig, Germany)
14. **Cheng AJ**, et al (2005, 4) hTERT phosphorylation is essential for telomerase activation and the holoenzyme assembly in oral cancer cells. Proc Am Assoc Cancer Res. (The 96th AACR, Anaheim, CA, USA)
15. **Cheng AJ**, et al (2004, 6) Identification of differentially expressed genes in oral squamous cell carcinoma. The 6th International Head & Neck Cancer Conference. (Washington DC, USA)
16. **Cheng AJ**, Chen I, Wang H, Liao C, Hsieh L, Chang J. (9, 2003) Prognostic significance of telomerase activity in oral squamous cell carcinoma. Eur J Cancer 39 (sup 4): 50. (The ECCO12, Copenhagen, Denmark)
17. **Cheng A-J**, Chang JTC, Wang HM, Liao CT, Chen IH, Hsieh LL. (9, 2002) Prognostic significance of EGFR and Her-2 in oral cavity cancer associated with betel quid chewing. Radiother Oncol 64 (sup 1): s235. (The 21st ESTRO, Prague, Czech)

18. **Cheng A-J**, Chang JTC, Wang HM, Liao CT, Chen IH, Hsieh LL. (4, 2002) Anti-survivine autoantibody was frequently found in head and neck cancer patients and associated with disease severity. Proc Am Assoc Cancer Res 43: 224. (The 93rd AACR, San Francisco, CA, USA)
19. **Cheng A-J**, JT Chang, YL Chen. (3, 2001) Essential telomerase subunits for the full activity of telomerase. Proc Am Assoc Cancer Res 42: 248. (The 92nd AACR, New Orleans, LA, USA)
20. **Cheng A-J**, Chen L, Chang J, Liao C, Chen I, Hsieh L, and Wang H (9, 2000). Analysis of surgical margins with telomerase activity in head and neck cancer. Radiother Oncol 56 (sup 1): s189. (The 19th ESTRO, Istanbul, Turkey)
21. **Cheng A-J**, Chang JT, Tien LD, Chen IL, Yang HT (4, 2000). Three major subunits of telomerase (hTR, TR1 and hTERT) are all necessary for full activity of telomerase. Proc Am Assoc Cancer Res 41: 449. (The 91st AACR, San Francisco, CA, USA)
22. **Cheng A-J**, Chen LH, Chang JT, Chiu D (10, 1999). Poor prognosis was found in nasopharyngeal cancer patients with low glucose-6-phosphate-dehydrogenase. Eur J Cancer 35 (sup 4): s165. (The ECCO10, Vienna, Austria)
23. **Cheng A-J**, Chang JT, and Chiu D. (4, 1999) Poor prognosis was found in nasopharyngeal cancer patients with low glucose-6-phosphate-dehydrogenase. Proc Am Assoc Cancer Res 40: 316. (The 90th AACR, Philadelphia, PA, USA)
24. **Cheng A-J**, Chen L-H, Liao C-T, Chang JT, Wang TV. (9, 1998) Telomerase activity in human nasopharyngeal diseases. Radiother Oncol 48 (sup 1): s196. (The 17th ESTRO, Edinburg, Scotland, UK)
25. **Cheng A-J**, Lin LD, Chang JT and Wang TV. (10, 1997) Telomerase activity in benign and malignant human thyroid disorders. Eur Cancer Conf 33 (sup 8): 272. (The ECCO9, Hamburg, Germany)
26. **Cheng A-J**, Liao S-K, Chow S-K, Chen J-K, and Wang TV. (4, 1997) Telomerase activity during induction of differentiation in melanoma and glioma cells in culture. Proc Am Assoc Cancer Res 38: 508. (The 88th AACR, San Diego, CA, USA)

C. Book, Book Chapter

1. 醫學分子檢驗·第13章: 蛋白質體學及腫瘤胞至蛋白的研發。(陳盈汝、鄭恩加)。五南出版社。2009 第一版。
2. 臨床化學- 原理、步驟與關連性。合計圖書出版社。(編輯:趙啟淵。監修: 魏正舒、鄭恩加、沈武訓、顏秀娟)。合計圖書出版社。2003 第一版。
3. 通識版生物技術·第5章: 生物技術在臨床診斷上之應用。中華民國教育部發行。(趙崇義、鄭恩加)。1998 第一版。